Venebio

Executive Summary

Venebio is a life sciences research consultancy and AI-driven clinical decision support (CDS) company founded in 2013 and headquartered in Richmond, Virginia. The firm operates through two divisions: Venebio Consulting provides scientific research and litigation support, while Venebio Technologies develops AI-powered CDS tools aimed at improving medication management. Its flagship products, Venebio Opioid Advisor and Venebio Statin Advisor, deliver personalized, evidence-based recommendations to clinicians for safer opioid prescribing and statin therapy. By combining domain expertise with machine learning, Venebio addresses critical challenges in pain management and cardiovascular disease prevention, potentially reducing adverse drug events and healthcare costs. As a privately held company with no disclosed funding or valuation, Venebio operates in the competitive digital health and AI/ML space. The company's focus on opioid safety is particularly timely given the ongoing public health crisis, and its Statin Advisor targets a large patient population with high rates of statin underutilization. Venebio's dual revenue streams from consulting and technology provide some financial resilience. However, the lack of public traction or partnerships suggests the company is still in early commercialization. Success will depend on achieving clinical validation, securing healthcare system contracts, and navigating regulatory pathways for its CDS tools. If Venebio can demonstrate improved outcomes, it has potential for growth, but visibility remains limited.

Upcoming Catalysts (preview)

• Q1 2027FDA Clearance or 510(k) for Opioid Advisor30% success
• Q2 2026Major Health System Partnership20% success
• Q3 2026Publication of Clinical Validation Study50% success